161 related articles for article (PubMed ID: 38730256)
1. m
Li S; Feng T; Liu Y; Yang Q; Song A; Wang S; Xie J; Zhang J; Yuan B; Sun Z
Int J Oral Sci; 2024 May; 16(1):36. PubMed ID: 38730256
[TBL] [Abstract][Full Text] [Related]
2. Histone Deacetylase Inhibitor Panobinostat Benefits the Therapeutic Efficacy of Oncolytic Herpes Simplex Virus Combined with PD-1/PD-L1 Blocking in Glioma and Squamous Cell Carcinoma Models.
Wu Y; Chen X; Wang L; Zhou X; Liu Y; Ji D; Ren P; Zhou GG; Zhao J
Viruses; 2022 Dec; 14(12):. PubMed ID: 36560800
[TBL] [Abstract][Full Text] [Related]
3. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.
Hirata-Nozaki Y; Ohkuri T; Ohara K; Kumai T; Nagata M; Harabuchi S; Kosaka A; Nagato T; Ishibashi K; Oikawa K; Aoki N; Ohara M; Harabuchi Y; Uno Y; Takei H; Celis E; Kobayashi H
J Transl Med; 2019 Jun; 17(1):207. PubMed ID: 31221178
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis B virus-triggered PTEN/β-catenin/c-Myc signaling enhances PD-L1 expression to promote immune evasion.
Sun Y; Yu M; Qu M; Ma Y; Zheng D; Yue Y; Guo S; Tang L; Li G; Zheng W; Wang M; Guo D; Li C
Am J Physiol Gastrointest Liver Physiol; 2020 Jan; 318(1):G162-G173. PubMed ID: 31604033
[TBL] [Abstract][Full Text] [Related]
5. HPV16 E5 Mediates Resistance to PD-L1 Blockade and Can Be Targeted with Rimantadine in Head and Neck Cancer.
Miyauchi S; Sanders PD; Guram K; Kim SS; Paolini F; Venuti A; Cohen EEW; Gutkind JS; Califano JA; Sharabi AB
Cancer Res; 2020 Feb; 80(4):732-746. PubMed ID: 31848196
[TBL] [Abstract][Full Text] [Related]
6. The let-7 family of microRNAs suppresses immune evasion in head and neck squamous cell carcinoma by promoting PD-L1 degradation.
Yu D; Liu X; Han G; Liu Y; Zhao X; Wang D; Bian X; Gu T; Wen L
Cell Commun Signal; 2019 Dec; 17(1):173. PubMed ID: 31881947
[TBL] [Abstract][Full Text] [Related]
7. Oncolytic herpesvirus expressing PD-L1 BiTE for cancer therapy: exploiting tumor immune suppression as an opportunity for targeted immunotherapy.
Khalique H; Baugh R; Dyer A; Scott EM; Frost S; Larkin S; Lei-Rossmann J; Seymour LW
J Immunother Cancer; 2021 Mar; 9(4):. PubMed ID: 33820820
[TBL] [Abstract][Full Text] [Related]
8. Programmed Death-1/Programmed Death-Ligand 1-Axis Blockade in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Stratified by Human Papillomavirus Status: A Systematic Review and Meta-Analysis.
Xu Y; Zhu G; Maroun CA; Wu IXY; Huang D; Seiwert TY; Liu Y; Mandal R; Zhang X
Front Immunol; 2021; 12():645170. PubMed ID: 33897693
[TBL] [Abstract][Full Text] [Related]
9. Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells.
Lee MY; Robbins Y; Sievers C; Friedman J; Abdul Sater H; Clavijo PE; Judd N; Tsong E; Silvin C; Soon-Shiong P; Padget MR; Schlom J; Hodge J; Hinrichs C; Allen C
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741731
[TBL] [Abstract][Full Text] [Related]
10. Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancer.
Crespo-Rodriguez E; Bergerhoff K; Bozhanova G; Foo S; Patin EC; Whittock H; Buus R; Haider S; Muirhead G; Thway K; Newbold K; Coffin RS; Vile RG; Kim D; McLaughlin M; Melcher AA; Harrington KJ; Pedersen M
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32759235
[TBL] [Abstract][Full Text] [Related]
11. CDK7 inhibitor THZ1 enhances antiPD-1 therapy efficacy via the p38α/MYC/PD-L1 signaling in non-small cell lung cancer.
Wang J; Zhang R; Lin Z; Zhang S; Chen Y; Tang J; Hong J; Zhou X; Zong Y; Xu Y; Meng R; Xu S; Liu L; Zhang T; Yang K; Dong X; Wu G
J Hematol Oncol; 2020 Jul; 13(1):99. PubMed ID: 32690037
[TBL] [Abstract][Full Text] [Related]
12. Systemic delivery of glycosylated-PEG-masked oncolytic virus enhances targeting of antitumor immuno-virotherapy and modulates T and NK cell infiltration.
Liang Y; Wang B; Chen Q; Fu X; Jiang C; Lin Z; Zhuang Q; Zeng Y; Liu X; Zhang D
Theranostics; 2023; 13(15):5452-5468. PubMed ID: 37908722
[No Abstract] [Full Text] [Related]
13. N
Liu Z; Wang T; She Y; Wu K; Gu S; Li L; Dong C; Chen C; Zhou Y
Mol Cancer; 2021 Aug; 20(1):105. PubMed ID: 34416901
[TBL] [Abstract][Full Text] [Related]
14. NOTCH-Induced MDSC Recruitment after oHSV Virotherapy in CNS Cancer Models Modulates Antitumor Immunotherapy.
Otani Y; Yoo JY; Lewis CT; Chao S; Swanner J; Shimizu T; Kang JM; Murphy SA; Rivera-Caraballo K; Hong B; Glorioso JC; Nakashima H; Lawler SE; Banasavadi-Siddegowda Y; Heiss JD; Yan Y; Pei G; Caligiuri MA; Zhao Z; Chiocca EA; Yu J; Kaur B
Clin Cancer Res; 2022 Apr; 28(7):1460-1473. PubMed ID: 35022322
[TBL] [Abstract][Full Text] [Related]
15. IL-12 Expressing oncolytic herpes simplex virus promotes anti-tumor activity and immunologic control of metastatic ovarian cancer in mice.
Thomas ED; Meza-Perez S; Bevis KS; Randall TD; Gillespie GY; Langford C; Alvarez RD
J Ovarian Res; 2016 Oct; 9(1):70. PubMed ID: 27784340
[TBL] [Abstract][Full Text] [Related]
16. APE1 facilitates PD-L1-mediated progression of laryngeal and hypopharyngeal squamous cell carcinoma.
Wang J; Lun L; Jiang X; Wang Y; Li X; Du G; Wang J
Int Immunopharmacol; 2021 Aug; 97():107675. PubMed ID: 33964809
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin Alters Antitumor Immunity and Synergizes with PD-1/PD-L1 Inhibition in Head and Neck Squamous Cell Carcinoma.
Tran L; Allen CT; Xiao R; Moore E; Davis R; Park SJ; Spielbauer K; Van Waes C; Schmitt NC
Cancer Immunol Res; 2017 Dec; 5(12):1141-1151. PubMed ID: 29097421
[TBL] [Abstract][Full Text] [Related]
18. Chemopreventive and chemotherapeutic actions of mTOR inhibitor in genetically defined head and neck squamous cell carcinoma mouse model.
Sun ZJ; Zhang L; Hall B; Bian Y; Gutkind JS; Kulkarni AB
Clin Cancer Res; 2012 Oct; 18(19):5304-13. PubMed ID: 22859719
[TBL] [Abstract][Full Text] [Related]
19. Expression of PD-1/PD-L1 in head and neck squamous cell carcinoma and its clinical significance.
Chen SW; Li SH; Shi DB; Jiang WM; Song M; Yang AK; Li YD; Bei JX; Chen WK; Zhang Q
Int J Biol Markers; 2019 Dec; 34(4):398-405. PubMed ID: 31674884
[TBL] [Abstract][Full Text] [Related]
20. Enhancing Therapeutic Efficacy of Oncolytic Herpes Simplex Virus with MEK Inhibitor Trametinib in Some BRAF or KRAS-Mutated Colorectal or Lung Carcinoma Models.
Zhou X; Zhao J; Zhang JV; Wu Y; Wang L; Chen X; Ji D; Zhou GG
Viruses; 2021 Sep; 13(9):. PubMed ID: 34578339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
